As per our research report, the global antibody drug conjugates market size was valued at USD 14.72 billion in 2022 and this value is further estimated to be growing at a CAGR of 24.74% from 2022 to 2027.
Browse details of the report @ https://www.marketdataforecast.com/market-reports/antibody-drug-conjugates-market
The COVID-19 pandemic has affected the entire supply chain of the medical industry, primarily due to severe blockades in several regions. The COVID-19 pandemic has affected economies in different parts of the world in three ways. Firstly, by directly affecting production and demand, secondly by disrupting distribution channels, and lastly by the economic impact on business and financial markets. Therefore, the effects of the coronavirus (COVID-19) pandemic are expected to limit the growth of the global antibody-drug conjugate market due to the discontinuation of cancer screening and the postponement of hospital visits associated with migration and cancer stage outcomes.
The global antibody drug conjugates market is driven primarily by rising cancer rates around the world. Factors such as smoking, unhealthy diet, obesity, and alcohol are the main causes of increasing cancer cases worldwide. ADCs are designed to eliminate cancer cells only without damaging normal cells. This is a major advantage of ADCs as intact healthy cells allow for faster patient recovery. The rise in the worldwide geriatric population, the growing occurrence of various sorts of cancers worldwide, and growing investments with the aid of using authorities our bodies in pharmaceutical studies & improvement sports for the extra superior most cancers pills and therapeutics are the various primary factors using the worldwide antibody-drug conjugates market sales increase.
Other essential benefits of those pills are better tumor selectivity, restrained systemic exposure, and multiplied drug tolerability. Increasing preclinical studies programs, the growing variety of medical trials for brand new most cancers therapeutics, the developing emphasis of pharmaceutical agencies on new drug discovery & improvement, and the emergence of superior antibody remedies are a number of the opposite essential elements using sales increase of the worldwide antibody-drug conjugates market significantly.
The increasing prevalence of cancer around the world, unhealthy urban lifestyles, and increased use of tobacco and alcohol in all regions are major cancer risk factors. The increase will reach 19 million. The growing demand for low-cost, high-quality cancer treatments is expected to drive the ADC market during the forecast period. The new prevalence of breast cancer is expected to drive the growth of the global antibody-drug conjugate market. According to the WHO, approximately 2.26 million new cases of breast cancer were diagnosed worldwide in 2020, with estimated cancer death of 685,000. There are three antibody-drug conjugate products for the treatment of breast cancer. Trodelvy by Gilead Sciences, Inc. Enhertu by AstraZeneca; Kadcyla from Hoffmann-La Roche Ltd. The provision of these drugs within the patient support program is expected to drive market growth.
Antibody-drug conjugates have therapeutic potential and pose both technical and developmental challenges. Antibody-drug conjugates are considered to be a new era of therapeutics. They combine the targeting ability of monoclonal antibodies with the target-specific cell-killing ability of cytotoxic drugs. The success of this technology was made possible only by facilitating technological progress. Antibody-drug conjugates are a new class of treatment that is drawing the attention of both large and small pharmaceutical companies. In addition, increased research activity on antibody therapy, preclinical research, increased research on late-stage drug discovery, increased research on oncological disorders, and increased collaboration between research institutions, biotechnology, and biopharmaceutical companies are on the market. It is expected to transform the progress of the antibody-drug discovery conjugate market.
Challenges related to ADC manufacturing are impacting the market for antibody-drug conjugates. ADC manufacturing facilities require significant capital investment and extensive specialized training for operators. The development of the ADC process is complex because it requires optimization of additional process steps not present in the production of traditional monoclonal antibodies. Antibody-drug conjugate reaction followed by drug purification. In addition, antibody-drug conjugates must be prepared in a sterile environment and operators must protect against highly toxic drug compounds, causing operational problems.
Avail sample market brochure of the report to evaluate report usefulness; get a copy @ https://www.marketdataforecast.com/market-reports/antibody-drug-conjugates-market/request-sample
KEY MARKET INSIGHTS:
Based on Product Type:
The number of companies developing techniques for antibody-drug conjugate technology has not changed significantly in recent years. Increased investment from pharmaceutical and biotechnology companies is expected to drive the market. Based on the product type, the market is divided into Adcertis and Kadcyla.
Adcetris (brentuximab vedotin) is a patient suffering from classical Hodgkin lymphoma (HL) after the failure of at least two multidrug chemotherapy regimens, patients who are not candidates for auto-HSCT, or patients who have failed autologous hematopoietic stem cell transplantation. It is a drug that is indicated for., HL patients at risk of recurrence or progression as consolidation after automated HSCT, and lymphoma patients after failure of at least one previous multidrug chemotherapy regimen.
Based on Technology:
The global antibody-drug conjugate market is divided into cleavable linkers, non-cleavable linkers, and linker-less technologies. The uncut linker segment held the largest revenue share in the global market in 2020, primarily due to factors such as increased awareness of the benefits of uncut linkers over cleavable linkers, including Improved plasma stability, and expanded treatment window, improved stability, and tolerability.
Based on Application:
The blood cancer segment is expected to dominate the other segments in terms of the fastest revenue CAGR during the forecast period. Blood cancer is one of the most common types of cancer and mainly affects the elderly. Increasing prevalence of blood cancer worldwide, increasing research and development activities for advanced and effective ADCs to treat the disease, increasing regulatory approvals for various newly developed ADCs, and blood. The development of new targeted therapies for cancer is a key driver of growth in this segment.
Regional Analysis:
North America is the most COVID-influenced area across the world. Because of the flare-up of COVID19, the market is expected to face slight difficulty in attributing to the postponement in diagnosis, drug deficiencies, and others. The antibody-drug conjugate market in North America is exceptionally competitive due to the presence of an enormous level of market players. North America is expected to control the worldwide market rapidly because of the expanding multiplication of technologically innovative technologies in the countries of the region such as the United States, Canada, and Mexico. North America is a very developed region as far as clinical information, and the utilization of ADCs is considered and makes up the vast majority of the established market. For example, in April 2021, Pfizer acquired Amplyx Pharmaceuticals Inc. to develop antibody-drug conjugates and other cancer therapies.
Europe is expected to hold the second-largest market share in the global antibody-drug conjugate market. The expansion of government initiatives and the growing number of APAC biotechnology and biopharmaceutical companies are also driving the APAC antibody-drug conjugate market.
Competitive landscape:
Major players operating in the global antibody-drug conjugates market include F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Ltd., Astellas Pharma, ADC Therapeutics, Pfizer, Inc., Seagen, Inc., Daiichi Sankyo Company Ltd., and Oxford Biotherapeutics.
The report can be customized as per the requirements; talk to our team @ https://www.marketdataforecast.com/market-reports/antibody-drug-conjugates-market/customization
SEGMENTS COVERED UNDER THIS REPORT:
By Pipeline:
- Phase
- Mode of action
- Igg1 antibodies
- HER2 antibodies
- Technology
- Linker
By Technology:
- Seattle Genetics
- Immunogen
- Immunomedics
By End User:
- Research institutes
- Hospitals
- Clinics
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Browse Regional Reports:
- North America Antibody Drug Conjugates Market
- Europe Antibody Drug Conjugates Market
- APAC Antibody Drug Conjugates Market
- Latin America Antibody Drug Conjugates Market
- MEA Antibody Drug Conjugates Market
About MarketDataForecast:
Market Data Forecast is a firm working in market research, business intelligence, and consulting. We have rich research and consulting experience for various business domains to cater to individual and corporate clients’ needs.
Contact Us:
Market Data Forecast
Phone: +1-888-702-9626
Email: contact@marketdataforecast.com